SG11202003127WA - Methods for treating lymphomas - Google Patents
Methods for treating lymphomasInfo
- Publication number
- SG11202003127WA SG11202003127WA SG11202003127WA SG11202003127WA SG11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA SG 11202003127W A SG11202003127W A SG 11202003127WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating lymphomas
- lymphomas
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201708262R | 2017-10-06 | ||
PCT/SG2018/050509 WO2019070204A1 (en) | 2017-10-06 | 2018-10-08 | Methods for treating lymphomas |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003127WA true SG11202003127WA (en) | 2020-05-28 |
Family
ID=65994265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003127WA SG11202003127WA (en) | 2017-10-06 | 2018-10-08 | Methods for treating lymphomas |
Country Status (6)
Country | Link |
---|---|
US (1) | US20200325229A1 (en) |
EP (1) | EP3692174A4 (en) |
JP (1) | JP2020536111A (en) |
CN (1) | CN111479932A (en) |
SG (1) | SG11202003127WA (en) |
WO (1) | WO2019070204A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022241293A2 (en) * | 2021-05-14 | 2022-11-17 | Foundation Medicine, Inc. | Cd274 mutations for cancer treatment |
CN114507286B (en) * | 2022-04-18 | 2022-07-05 | 苏州百道医疗科技有限公司 | anti-PD-L1 recombinant rabbit monoclonal antibody and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150292022A1 (en) * | 2011-11-25 | 2015-10-15 | Singapore Health Services Pte Ltd. | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy |
CA2952181A1 (en) * | 2014-05-28 | 2015-12-03 | Dana-Farber Cancer Institute, Inc. | Activating jak kinase biomarkers predictive of anti-immune checkpoint inhibitor response |
WO2016175275A1 (en) * | 2015-04-30 | 2016-11-03 | 国立大学法人京都大学 | Method for predicting therapeutic effect of pd-1/pd-l1 inhibitor using abnormality in pd-l1(cd274) as index |
CN106987631A (en) * | 2017-04-01 | 2017-07-28 | 武汉赛云博生物科技有限公司 | A kind of immune group sequencing technologies for the adjoint diagnosis of PD 1/PD L1 blocking treatments |
-
2018
- 2018-10-08 EP EP18863900.9A patent/EP3692174A4/en not_active Withdrawn
- 2018-10-08 JP JP2020519426A patent/JP2020536111A/en active Pending
- 2018-10-08 SG SG11202003127WA patent/SG11202003127WA/en unknown
- 2018-10-08 CN CN201880078523.4A patent/CN111479932A/en active Pending
- 2018-10-08 WO PCT/SG2018/050509 patent/WO2019070204A1/en unknown
- 2018-10-10 US US16/754,068 patent/US20200325229A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN111479932A (en) | 2020-07-31 |
US20200325229A1 (en) | 2020-10-15 |
EP3692174A4 (en) | 2021-06-23 |
EP3692174A1 (en) | 2020-08-12 |
JP2020536111A (en) | 2020-12-10 |
WO2019070204A1 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251407A1 (en) | Methods for treating cancer | |
ZA201705673B (en) | Methods for treating skin | |
ZA201706616B (en) | Method for treating cancer | |
IL249454B (en) | Treating lymphomas | |
IL304252A (en) | Method for treating cancer | |
IL289947A (en) | Method for treating cancer | |
IL257691A (en) | Method for treating cancer | |
HK1244217A1 (en) | Methods for treating proteinopathies | |
HK1254258A1 (en) | Methods for treating cancer using apilimod | |
HK1250944A1 (en) | Methods for treating cancer | |
GB2567616B (en) | Treatment method | |
HK1248135A1 (en) | Combination method for treating cancer | |
HK1248133A1 (en) | Methods for treating neuroblastoma | |
HK1250942A1 (en) | Methods for treating cancer | |
GB2571601B (en) | Treatment method | |
HK1250943A1 (en) | Methods for treating cancer | |
SG11202001806TA (en) | Treatment method | |
SG11202003127WA (en) | Methods for treating lymphomas | |
IL270867A (en) | Treatment method | |
SG10201508795XA (en) | Method for treating cancer | |
HK1256371A1 (en) | Methods for treating tumours | |
HUP1700275A2 (en) | Process for self-host |